Sun Pharmaceutical Industries share price
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,758.00.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,19,404 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 34.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 May 2026
- 5.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.92%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 16.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 22 May 2026
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 10,64,52860.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 31 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹15,300 Crup 4.71%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,901 Crup 7.07%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 19.0%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 30 Oct | Dec 2024Filed 31 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 31 Jul | Sep 2025Filed 5 Nov | Dec 2025Filed 31 Jan | Mar 2026Filed 22 May | Jun 2026Filed 31 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 22.9% | 21.3% | 16.6% | 16.6% | 21.6% | 21.8% | 18.5% | 19.0% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 73% of 2,215 trading days since Nov 2016.
At or below today's level on 65% of 1,969 trading days since Nov 2018.
At or below today's level on 65% of 1,969 trading days since Nov 2018.
At or below today's level on 59% of 2,474 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +2.2% | +4.8% | −3.4% | 0.9% |
| 3 years | +22.2% | +10.6% | +9.7% | 0.9% |
| 5 years | +25.1% | +31.6% | −5.7% | 1.0% |
Mutual funds holding it
517 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 203 of the 277 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 7 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 154
- CutCut. Funds that held fewer shares than at the end of the month before.
- 123
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 226
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 SBI Nifty 50 ETFSBI Mutual Fund | 2,05,37,460 | 1.84% | ₹3,730.8 Cr |
| SBI BSE Sensex ETFSBI Mutual Fund | 1,45,07,940 | 2.28% | ₹2,640.4 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 1,37,69,894 | 4.37% | ₹2,501.4 Cr |
| ICICI Prudential Aggressive Hybrid FundICICI Prudential Mutual Fund | 98,53,039 | 3.53% | ₹1,789.9 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 87,46,339 | 1.55% | ₹1,588.9 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 87,39,509 | 2.08% | ₹1,587.6 Cr |
| SBI Aggressive Hybrid FundSBI Mutual Fund | 79,00,000 | 1.67% | ₹1,435.1 Cr |
 UTI Nifty 50 ETFUTI Mutual Fund | 70,43,274 | 1.84% | ₹1,279.5 Cr |
| UTI BSE Sensex ETFUTI Mutual Fund | 68,36,189 | 2.28% | ₹1,244.2 Cr |
 Nippon India ETF Nifty 50 BeESNippon India Mutual Fund | 65,93,147 | 1.84% | ₹1,197.7 Cr |
Peers and competitors
Pharmaceuticals, 215 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Sun Pharmaceutical Industries in market cap. 1 company in its own group left out: one owns more than half of the other, directly or through a company it controls, or one owner more than half of both.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Divi's LaboratoriesDIVISLAB | 2,37,594 | 81.2 | 14.2 | 59.0 | +16.3% | +26.8% | 18.4% | 20.8% | 0.34% |
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 7 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 5 Feb 2026 | Interim | ₹11.00 |
| 7 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.50 |
| 6 Feb 2025 | Interim | ₹10.50 |
| 12 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 9 Feb 2024 | Interim | ₹8.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
23 Oct · Business
20 Oct · Business
15 Oct · Analysts
13 Oct · Rating
12 Oct · Management
Sun Pharmaceutical Industries share price by year
Each calendar year to 2025.Sun Pharmaceutical Industries share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,719.70 | −8.8% | 1,889.95 | 1,563.30 |
| 2024 | 1,886.35 | +49.8% | 1,948.70 | 1,260.25 |
| 2023 | 1,259.45 | +25.8% | 1,262.15 | 925.85 |
| 2022 | 1,001.40 | +18.4% | 1,051.95 | 793.40 |
| 2021 | 845.70 | +42.8% | 845.70 | 564.35 |
| 2020 | 592.35 | +36.9% | 592.35 | 324.50 |
| 2019 | 432.55 | +0.5% | 478.85 | 366.80 |
| 2018 | 430.50 | −24.6% | 677.40 | 399.00 |
| 2017 | 571.15 | −9.3% | 710.80 | 450.00 |
| 2016 | 630.00 | −23.2% | 882.45 | 609.15 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,757.40 | 1,765.40 | 1,735.20 | 1,748.00 | 1,745.90 | 10,64,528 | 60.0% |
| 22 Oct 2026 | 1,732.00 | 1,758.00 | 1,719.10 | 1,758.00 | 1,745.38 | 17,78,519 | 65.9% |
| 21 Oct 2026 | 1,753.00 | 1,755.60 | 1,721.10 | 1,745.10 | 1,734.43 | 23,16,342 | 66.2% |
| 19 Oct 2026 | 1,758.80 | 1,768.90 | 1,735.30 | 1,743.00 | 1,747.00 | 8,29,445 | 53.9% |
| 16 Oct 2026 | 1,762.20 | 1,764.90 | 1,743.50 | 1,758.80 | 1,754.83 | 15,22,459 | 62.6% |
| 15 Oct 2026 | 1,736.00 | 1,778.00 | 1,734.10 | 1,764.00 | 1,765.35 | 13,76,380 | 65.9% |
| 14 Oct 2026 | 1,770.10 | 1,770.10 | 1,725.50 | 1,746.40 | 1,739.85 | 18,08,782 | 68.3% |
| 13 Oct 2026 | 1,760.00 | 1,770.70 | 1,750.60 | 1,770.70 | 1,762.86 | 11,91,057 | 61.1% |
| 12 Oct 2026 | 1,764.30 | 1,776.60 | 1,750.00 | 1,760.00 | 1,760.46 | 11,41,685 | 59.8% |
| 9 Oct 2026 | 1,756.20 | 1,776.80 | 1,751.00 | 1,760.00 | 1,764.95 | 13,46,107 | 61.4% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 29 Jul 2013 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 25 Nov 2010 | Split | 0.2000 | Each share became 5. |
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Limited is a pharmaceutical company that operates in more than 100 countries. Its business spans Innovative Medicines, branded generics, generics and active pharmaceutical ingredients (APIs), and it sells consumer healthcare products in more than 25 countries. It has more than 47,000 employees, and its registered office is in Vadodara, Gujarat.
The business is organised into five groups: India formulations, US formulations, Emerging Markets formulations, Rest of World formulations, and API and others. In India it is the largest pharmaceutical company by market share, for the 12 months to June 2026. Emerging Markets formulations are sold in more than 80 countries, with Romania, Russia, South Africa, Brazil and Mexico as focus markets. Rest of World covers markets that include Western Europe, Canada, Japan, Australia and New Zealand, and Israel.
In its Innovative Medicines business it markets 29 products globally, in dermatology, ophthalmology and onco-dermatology. In the year to March 2026 it launched two new treatments in the US, LEQSELVI and UNLOXCYT. It has 40 manufacturing facilities with capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules. Its research covers global clinical trials, early-stage novel research and generics.
It was incorporated in 1993. It entered the US generics market through its 1997 acquisition of Caraco and acquired Taro Pharma, based in Israel, in 2010. Taro is now a 100% subsidiary. It acquired DUSA Pharma in the US in 2012, merged with Ranbaxy in 2015, and acquired Checkpoint Therapeutics, an immunotherapy and targeted oncology company, in 2025.
- Legal name
- Sun Pharmaceutical Industries Limited
- NSE symbol
- SUNPHARMA
- BSE code
- 524715
- ISIN
- INE044A01036
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 1994 on BSE, Feb 1995 on NSE
- Face value
- ₹1
- CIN
- L24230GJ1993PLC019050
- Corporate identity number, the registrar of companies' code for it